Investors Guide
NEWLY EMERGING MARIJUANA MARKETS
ABcann-desktop ABcann-mobile

PROFIT-MAKING ALERTABCANN GLOBAL (OTC: ABCCF) (TSX.V: ABCN) JUST HAD ITS IPO.

PROFIT-MAKING ALERT
ABCANN GLOBAL
(OTC: ABCCF) (TSX.V: ABCN)
JUST HAD ITS IPO.

The next major marijuana success story just hit the markets.

It’s a mid-size marijuana grower that’s on it’s way to major success.

It’s already implementing one of the largest expansions in the world right now.

And it just signed a MASSIVE deal...

It’s been working away at creating the most cost-effective and highest-quality indoor marijuana farming techniques and it’s already producing marijuana at twice the rate of its top competitors.

It’s earned the backing of pharmaceutical executives, renowned marijuana scientists, and top agriculture experts.

It’s still trading for a less than it’s competitors did BEFORE their shares went on to rise more than 711% and 887%.

And... it’s available to new investors now.

The company is ABcann Global (OTC: ABCCF) (TSX.V ABCN) and if you’re looking for the next big marijuana story, this is it.

#1 Marijuana Stock For 2017

#1 Marijuana Stock For 2017

In April, 2017, ABcann (OTC: ABCCF) (TSX.V ABCN)
became available to public investors.

In April, 2017, ABcann (OTC: ABCCF) (TSX.V ABCN) became available to public investors.

The company joined a handful of select, government-backed marijuana growers which have been soaring higher. Now that it’s public, ABcann will officially join the likes of:

Canopy Growth ( TWMJF / WEED.cn ) which ran 711% from its IPO

canopy-growth-desktop canopy-growth-mobile

Aphria Inc (APHQF / APH.cn) is another one. It ran up 938% since it hit the public markets.

aphira-inc-desktop aphira-growth-mobile
abcann-profit-alert-desktop profit-alert-last-mobile

Aurora Cannabis (ACBFF / ACB.cn) climbed 887% after its IPO.

aurora-cannabis-desktop aurora-cannabis-mobile

SupremePharma (SPRWF / SL.cn) has soared 1364% from its IPO.[AM1]

supremepharma-desktop supremepharma-desktop
ABcann (OTC: ABCCF) (TSX.v ABCN) is the NEXT one of those.

It has the very real potential to run up as much as 1364% just like the other Canadian marijuana growers.

However, as you’ll see today, it could blow them all away in a matter of months.

ABCann could become the world’s first global marijuana powerhouse...

It has the very real potential to run up as much as 1364% just like the other Canadian marijuana growers.

1. ABcann’s path to growth is protected by the Government!

Since 2013, more than 1,600 companies have applied to Health Canada to become a licensed producer (LP) of medical marijuana.

Only 5 companies won coveted LP status in 2013, just another 14 made the cut in 2014.

Getting an official license is like winning the lottery for marijuana companies in Canada.

And you remember already how they rose 711%, 887%, and 938%, and as much as 1364%.

ABcann has its license too and has now joined that exclusive group.

However, ABcann was one of the first companies to do get the license and has parlayed its “head start” into something none of these companies have achieved.

2. ABcann is a marijuana technology powerhouse

It’s about Production per square foot.

Here’s where ABcann stands out among Canada’s licensed marijuana producers—technology.

Yes, it’s a low-cost producer like Aphria. Yes, it’s a high-quality producer like Tweed (Canopy). But its competence is unique!

ABcann can grow every one or its 14 MMJ strains to exact specifications for precise THC and cannabidiol (CBD) balances.

Every plant, every time.

And it can scale up to infinity. ABcann can replicate its proprietary growing system for any MJ strain anywhere.

3. Barriers to entry are too high for mass competition

Canada’s not like the “Wild West” system in some US states like Colorado where almost anyone can get in the business somehow. Canada’s marijuana growers enjoy the next best thing to no competition! It’s that hard to break in.

Since 2013, Health Canada (think Canada’s FDA) has approved less than 2% of applications to grow marijuana commercially.

4. Ramping up production in 2017

ABcann has laid out a plan to rapidly expand production.

Now, ABcann is no start-up marijuana company. It already has a 14,500 square foot growth facility in Ontario, Canada.

This is where it already achieved its industry-leading production 250 grams of marketable marijuana per square foot (more than double the average among Canadian marijuana producers).

The reason it’s going public is to raise another C$23 million to get started on the next major expansion project.

This project is expected to add an additional 71,000 square feet to ABcann’s total marijuana footprint.

After completed, the massive expansion combined with ABcann’s market-leading production methods will put it on par with Canadian marijuana producers valued at five times more than ABcann will be during its IPO.

This is the most perfect wash, rinse, repeat model in the marijuana industry

5. ABcann’s ultimate goal is global dominance.

It will aim to be the first INTERNATIONAL company to have advanced, high-quality marijuana products available on multiple continents.

From its home just across the U.S. border in Ontario, ABcann plans to expand in Canada to Saskatchewan and British Columbia.

It is in final stages of competition for a license in Hawaii…

It’s already supplying research-grade marijuana to an Israeli pharmaceutical company…

And it’s working on prospects in Australia and Germany.

6. Backed by essential expertise.

A successful marijuana company needs expertise in pharmaceuticals, agriculture and specialized medical marijuana science.

ABcann has it all.

And oh yeah, did we mention this?

Heads You Win, Tails I Win:

You’re not going to see opportunities like this come along often.

What if I told you Jeff Bezos, the founder of Amazon, just announced he’s putting $1.2 billion into a new tech start-up…

Bezos cited the advanced efficiency, early leadership, and exceptionally bright future of this rapidly growing start-up as his reason for the massive investment.

Would you be interested? Of course you would.

But what if I told you that you could also buy in at 55% less than Bezos in the exact same start-up? It’d be a no-brainer, right? Sure it would.

Well, that’s the kind of opportunity you’re going to see with ABcann.

Check this out... Major Marijuana Investment Just Announced

Marijuana investors aren’t going to see an opportunity like this for a long time.

A major marijuana deal was just struck between a hot, innovative marijuana finance company and one of the fastest-growing marijuana producers in North America.

What does that mean?

The conclusion here is really simple: The leading marijuana finance company is paying above top dollar merely for the right to finance one of the most effective Canadian marijuana growers in hopes of being allowed to put up all the money for half the profits on a project down the line.

What a deal right? Well, it is. But getting to that conclusion isn’t so simple for many investors. That will change though. And by the the time they do put it all together, this opportunity will have passed you by. Don’t let it.

Just follow the breakdown of this major marijuana deal below you’ll be able to get in on the big winner resulting from it all.

Major Marijuana Investment Just Announced

Marijuana investors aren’t going to see an opportunity like this for a long time.

A major marijuana deal was just struck between two leading major marijuana companies.

On one side is ABcann Global (OTC: ABCCF) (TSXV:ABCN), a well-funded, fully licensed Canadian marijuana producer with huge growth targets, market-leading production efficiency, and is valued at a price that makes it the cheapest Canadian marijuana stock on the market today.

On the other side is Cannabis Wheaton (TSXV:CBW / OTCBB:KWFLF), an innovative marijuana financing company headed by the early leaders in the Canadian marijuana industry and is the process of completing an $80 million capital raise for itself.

The two have struck a deal which provides funding to accelerate the growth for ABcann, will eventually give Cannabis Wheaton a large stream of marijuana production, and gives early investors an opportunity to get in it all at 55% below the price paid by Cannabis Wheaton.

The Seed Investor’s breakdown of the deal below goes over the details of the deal and how you can benefit from it all.

ABcann Global and Cannabis Wheaton Strike Major Marijuana Deal

ABcann and Cannabis Wheaton got together to announce a major deal that’s going to set them both on a much more rapid growth trajectory than anyone previously expected.

The structure of the deal is a bit complicated, but if you take a look at the individual parts, there’s a clear way you can profit from it all.

Below is a breakdown of the key parts of the announcement and which company gets what and what it means for the futures of these two rising marijuana powerhouses.

What ABcann Gets:

Equity Investment (Stage 1):

On the date that is the earlier of 10 days of the final closing of Cannabis Wheaton’s previously announced financing or by June 30, 2017, Cannabis Wheaton will subscribe for $15-million of ABcann common shares at an agreed-upon valuation of $2.25 per ABcann share.

What it means:

ABcann, which closed Monday at 98 cents per share, is getting financed for $15 million at $2.25 a share.

That’s a 134% premium to the market price.

Investors who bought are paying less than half of what Cannabis Wheaton is getting in at.

That alone makes ABcann, at it’s current price, a virtual steal right there.

Equity Investment (Stage 2):

On the date that is the earlier of 10 days of Cannabis Wheaton raising an aggregate of $150-million or March 31, 2018, Cannabis Wheaton will subscribe for an additional $15-million at a price per ABcann share equal to the greater of two times the 10-day volume-weighted average trading price of the ABcann shares at the relevant time or $2.25.

What it means:

Again, ABcann gets funded at $2.25 per share. That’s more than double the current market price. It’s a great funding source with far less dilution for shareholders.

Advanced Expansion Project:

Upon completion of the $30-million investment and upon accepting ABcann’s construction budget and timeline for the construction of the expansion production area, Cannabis Wheaton will provide all necessary financing to complete the construction of the expansion production area.

This expansion will be in addition to ABcann’s current 100,000-square-foot facility that is commencing construction imminently.

What it means:

ABcann gets $30 million up front at way-above-market price to fund the rapid build out of its 100,000 square foot, state-of-the-art marijuana production facility.

The $30 million investment goes right into that.

And here’s the real key: Cannabis Wheaton gets no part of that expansion.

At this point, Cannabis Wheaton is a regular shareholder just like you or anyone else who bought into ABcann while it’s still valued at a fraction of its peers.

ABcann has the right people in the right place

We don’t usually fawn over company bios—because the business should speak for itself. But with in this new Marijuana Space, reputation is indispensable, and experience is priceless.

ABcann’s management and advisors include:

Marijuana Science Experience

Raphael Mechoulam, PhD - known as “The Father of Medical Marijuana” is an organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem.

He is the first scientist to isolate cannabidiol sdff (CBD) in 1963 and first scientist to isolate tetrahydrocannabinol (THC).

Mechoulam has also won over 25 academic awards including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

Agriculture Science Experience

Mike Dixon, PhD - Professor, School of Environmental Sciences, Director of the Controlled Environment Systems Research Facility, University of Guelph.

He formed the Space and Advanced Life Support Agriculture (SALSA) program.

Dixon also leads the world in technology developments and research dedicated to studying plant and microbial interactions in advanced life support systems.

Pharmaceutical Experience

Paul Lucas - Is former President and CEO of GlaxoSmithKline Canada for 18 years.

He was also the former Chairman for TM Bioscience, Director for Biochem Pharma, the Toronto Regional Research Alliance, Montreal inVivo, and AllerGen. Lucas is currently a Director of the Ontario Genomics Institute, consultant with Queen’s University, an advisor to Lumira Capital and RnA Diagnostics, and Chair of Life Sciences Ontario.

It’s not often you get to see a great company... In an industry set to grow 50%+ a year for years to come... In a position where government is actually stifling new entrants... With a proven technological edge years ahead of competitors… Backed by multiple industry heavyweights... And at a valuation which is a fraction of it’s competitors.

This is one of those times. And you get to see it right when it first opens to the public. Consider buying ABCann Global (OTC: ABCCF) (TSX.V ABCN) today.

abcann-profit-alert-desktop profit-alert-last-mobile

About Seed Investor

Seed Investor was created to provide comprehensive research and analysis the coming cannabis boom. The process of cannabis legalization throughout the U.S. and Canada has the potential to propel the industry from about $5 billion in 2014 to as much as $100 billion by 2020 and create a mountain of wealth in the process. The Seed Investor targets the best opportunities in this 1900%+ potential growth industry.

The Seed Investor Report disclaimer

The Seed Investor (TSI) SAFE HARBOR STATEMENT: Statements contained in this online report and document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. TSI provides no assurance as to the subject company’s plans or ability to affect any planned and/or proposed actions. TSI has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company or its agent and related sources believed by TSI to be reliable, but TSI provides no assurance, and none is given, as to the accuracy and completeness of this information.

DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. The Seed Investor is an independent subscriber/membersonly news website. This online report and document is a solicitation for membership in the The Seed Investor service. The Seed Investor did not receive any Direct compensation with respect to the writing of this online report and document. This stock was chosen to be profiled after The Seed Investor completed due diligence on the stock. The Seed Investor expects to generate new membership revenue, the amount of which is unknown at this time, to its website through the distribution of this online report and document. This constitutes a conflict of interest as to TSI’s ability to remain objective in its communication regarding the subject company. Analysts, principals, associates and employees of TSI do not own or trade equities under coverage. For detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934. TSI is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement. Information contained herein contains forward looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov and the National Association of Securities Dealers (NASD) at http://www.nasd.com. The NASD has published information on how to invest carefully. Readers can review all public filings by companies at the SEC’s EDGAR page.

Third Party/Agency Disclaimer: Content of this message is published by The Seed Investor and sent to select our mailing list through various marketing media to provide readers with information on selected publicly-traded companies. Theseedinvestor.com newsletter (hereafter called “TSI”) is an information and marketing firm wholly owned by Dynamic Wealth Publishing, LLC and is not a financial analyst, investment adviser or broker/dealer. TSI is in the business of marketing and advertising companies to generate exposure of them by sending alerts to our subscribers for monetary compensation. Dynamic Wealth Publishing, LLC has been compensated thirty six thousand dollars from IR Media Services Inc. (a non-controlling third party) for advertising and promotional services.

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to ABcann Global. (ticker symbol (TXS: ABCN; OTCQB: ABCCF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in ABcann Global (TXS: ABCN; OTCQB: ABCCF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 

The information contained in this e-mail and in other Seed Investor communications are intended for general information purposes only. Seed Investor has not taken into account the specific investment objectives of any particular investor. You should always seek the counsel of a professional financial advisor before purchasing or selling stock. Seed Investor believes the sources of information to be reliable but Seed Investor does not guarantee the accuracy or completeness of the information provided on this website or in other Seed Investor communications, and expressly disclaims liability for any errors or omissions that may be contained in the information. (Read full disclaimer)